PTG-0861
Modify Date: 2025-08-25 12:46:40
PTG-0861 structure
|
Common Name | PTG-0861 | ||
|---|---|---|---|---|
| CAS Number | 2494082-34-5 | Molecular Weight | 360.24 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H9F5N2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PTG-0861PTG-0861 (JG-265) is a novel potent, selective HDAC6 inhibitor with IC50 of 5.92 nM, >36-fold selectivity over other HDACs.PTG-0861 (JG-265) displays HDAC6 cellular target engagement with EC50 of 0.59 uM (ELISA), has in vitro and cellular selectivity superior to HDAC6-selective inhibitor citarinostat (ACY-241).PTG-0861 (JG-265) demonstrates potency against several blood cancer cell lines (e.g. MV4-11, MM1S), whilst showing limited cytotoxicity against non-malignant cells and CD-1 mice.PTG-0861 (JG-265) exihibits promising in vitro pharmacokinetics achieved with good safety profile in cells and in vivo. |
| Name | PTG-0861 |
|---|
| Description | PTG-0861 (JG-265) is a novel potent, selective HDAC6 inhibitor with IC50 of 5.92 nM, >36-fold selectivity over other HDACs.PTG-0861 (JG-265) displays HDAC6 cellular target engagement with EC50 of 0.59 uM (ELISA), has in vitro and cellular selectivity superior to HDAC6-selective inhibitor citarinostat (ACY-241).PTG-0861 (JG-265) demonstrates potency against several blood cancer cell lines (e.g. MV4-11, MM1S), whilst showing limited cytotoxicity against non-malignant cells and CD-1 mice.PTG-0861 (JG-265) exihibits promising in vitro pharmacokinetics achieved with good safety profile in cells and in vivo. |
|---|---|
| References | 1. Justyna M Gawel, et al. Eur J Med Chem. 2020 Sep 1;201:112411. |
| Molecular Formula | C15H9F5N2O3 |
|---|---|
| Molecular Weight | 360.24 |